Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
Lenalidomide polarizes Th1 specific anti-tumor response and expands XBP-1 antigen-specific central memory CD3+CD8+ T cells against various solid tumors.
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.
A Phase 1b study of PVX-410 Vaccine in Combination with Pembrolizumab in Metastatic Triple Negative Breast Cancer (mTNBC)
A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response.
Dr. Noopur Raje on PVX-410 with durvalumab and lenalidomide in the treatment of SMM.
Pembrolizumab (anti-PD-1) treatment increases anti-tumor activities of XBP1/CD138/CS1-specific cytotoxic T lymphocytes against multiple myeloma.
Identification and Validation of HLA-A24 XBP1, CD138, CS1 Peptides: Induction of antigens-specific CD8 T cell Immunity using a Multi-peptide Cocktail. Preclinical basis for vaccine therapy in HLA-A24 patients with multiple myeloma and other cancers.
Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM).
Dr. Noopur Raje provides an overview of SMM.
Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM).
Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smouldering Multiple Myeloma (SMM).
Novel heteroclitic XBP1 peptides induce antigen-specific memory CD3+CD8+ T cells expressing critical T cell markers and transcription regulators.
Lenalidomide treatment enhances the anti-tumor activities of XBP1 specific cytotoxic T lymphocytes by increasing the frequency and tumor-specific response of central memory CD3+CD8+ T cells.
Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T lymphocytes targeting various solid tumors.
Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138, CS1 Peptides in Smoldering Multiple Myeloma.
Identification of CS1 Peptides for Induction of Antigen-Specific CTLs in Multiple Myeloma.
XBP-1 a Selective and Specific Target for Immunotherapy in Myeloma.
Development of Novel CD138 Antigen-Specific Peptide Capable of Eliciting Myeloma-Specific Cytotoxic T Lymphocytes Response.